Boston Scientific BSX
NYSE · Surgical & Medical Instruments & Apparatus · $63.2BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
After a story on BSX, the first close moved a median −3.11%. Up 1 of 3; over the next three trading days, a median −3.33%.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B | +19.9% | +14.0% | |
| Cost of Revenue (COGS) | $3.7B | $4.0B | $4.3B | $5.3B | $6.2B | +18.3% | +13.8% | |
| Gross Profit | $8.2B | $8.7B | $9.9B | $11.5B | $13.9B | +20.6% | +14.1% | |
| Selling, General & Admin (SG&A) | $4.4B | $4.5B | $5.2B | $6.0B | $6.9B | +15.1% | +12.1% | |
| Total Operating Expenses | $7.0B | $7.1B | $7.6B | $8.9B | $10.2B | +15.2% | +10.1% | |
| Operating Income (EBIT) | $1.2B | $1.6B | $2.3B | $2.6B | $3.6B | +38.8% | +31.8% | |
| Interest Expense | $341.0M | $470.0M | $265.0M | $305.0M | $349.0M | +14.4% | +0.6% | |
| Income Tax Expense | $36.0M | $443.0M | $393.0M | $436.0M | $493.0M | +13.1% | +92.4% | |
| GAAP Net Income | $1.0B | $698.0M | $1.6B | $1.8B | $2.9B | +56.7% | +29.1% | |
| Diluted EPS | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | +55.2% | +29.5% | |
| Diluted Shares | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B | +0.6% | +1.0% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $2.2B | $1.1B | $1.1B | $606.0M | $2.1B | +254.3% | −0.2% | |
| Inventory | $1.6B | $1.9B | $2.5B | $2.8B | $2.9B | +4.7% | +16.3% | |
| Total Current Assets | $6.3B | $5.8B | $6.5B | $6.9B | $8.8B | +27.1% | +8.6% | |
| Total Assets | $32.2B | $32.5B | $35.1B | $39.4B | $43.7B | +10.9% | +7.9% | |
| Total Current Liabilities | $4.3B | $3.8B | $4.9B | $6.4B | $5.4B | −15.0% | +6.2% | |
| Total Debt (Short + Long Term) | $5.1B | $4.8B | $5.3B | $6.6B | $5.1B | −22.5% | +0.2% | |
| Stockholders' Equity | $16.6B | $17.6B | $19.5B | $22.0B | $24.5B | +11.2% | +10.2% | |
| Net Cash / (Net Debt) | $-2.9B | $-3.7B | $-4.3B | $-6.0B | $-3.0B | +50.5% | — | |
| Invested Capital | $19.5B | $21.3B | $23.8B | $28.0B | $27.4B | −2.0% | +8.9% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $1.9B | $1.5B | $2.5B | $3.4B | $4.5B | +32.0% | +24.8% | |
| Depreciation & Amortization (D&A) | $1.1B | $1.1B | $1.2B | $1.3B | $1.4B | +7.8% | +5.8% | |
| Stock-Based Compensation (SBC) | $194.0M | $220.0M | $233.0M | $266.0M | $299.0M | +12.4% | +11.4% | |
| Capital Expenditures (CapEx) | $554.0M | $588.0M | $711.0M | $790.0M | $876.0M | +10.9% | +12.1% | |
| Free Cash Flow (FCF) | $1.3B | $938.0M | $1.8B | $2.6B | $3.7B | +38.3% | +29.1% | |
| True FCF (ex-SBC Owner Cash) | $1.1B | $718.0M | $1.6B | $2.4B | $3.4B | +41.2% | +31.5% | |
| Share Repurchases (Buybacks) | $0 | $0 | — | — | $0 | — | — | |
| Dividends Paid | $55.0M | $55.0M | $28.0M | $0 | $0 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.